← Back to All US Stocks

CSCIF Stock Analysis - COSCIENS Biopharma Inc. AI Rating

CSCIF OTC Perfumes, Cosmetics & Other Toilet Preparations A6 CIK: 0001113423
Recently Updated • Analysis: Mar 23, 2026 • SEC Data: 2026-03-23
AI Rating
SELL
95% Confidence

📊 CSCIF Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: SELL with 95% confidence

Investment Thesis

COSCIENS Biopharma lacks sufficient financial data to assess fundamental health, with only 1 metric available and no recent SEC filings. The company is inactive or non-reporting, making it impossible to evaluate profitability, liquidity, or operational performance.

CSCIF Strengths

  • -No strengths identified

CSCIF Risks

  • ! Complete absence of financial data - no revenue, earnings, or balance sheet information available
  • ! No recent SEC filings or data freshness - company appears non-reporting or dormant
  • ! Zero insider trading activity in past 90 days indicates lack of management confidence or company inactivity
  • ! Impossible to assess liquidity, solvency, or operational viability without fundamental financial statements
  • ! OTC listing with no reporting requirements compounds lack of transparency

Key Metrics to Watch

CSCIF Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

CSCIF Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

CSCIF vs Energy Sector

How COSCIENS Biopharma Inc. compares to Energy sector averages

Net Margin
CSCIF 0.0%
vs
Sector Avg 12.0%
CSCIF Sector
ROE
CSCIF 0.0%
vs
Sector Avg 14.0%
CSCIF Sector
Current Ratio
CSCIF 0.0x
vs
Sector Avg 1.3x
CSCIF Sector
Debt/Equity
CSCIF 0.0x
vs
Sector Avg 0.6x
CSCIF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CSCIF Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

CSCIF Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

CSCIF SEC Filings

Access official SEC EDGAR filings for COSCIENS Biopharma Inc. (CIK: 0001113423)

📋 Recent SEC Filings

Date Form Document Action
Sep 6, 2024 SC 13D formsc13d.htm View →
Jun 6, 2024 SC 13G formsc13g.htm View →
Jul 10, 2020 SC 13G ea124029-sc13gintra_aeterna.htm View →
Jul 7, 2020 SC 13G sc13g.htm View →
Feb 28, 2020 SC 13G d8484764_13-g.htm View →

Frequently Asked Questions about CSCIF

What is the AI rating for CSCIF?

COSCIENS Biopharma Inc. (CSCIF) has an AI rating of SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CSCIF's key strengths?

.

What are the risks of investing in CSCIF?

Complete absence of financial data - no revenue, earnings, or balance sheet information available. No recent SEC filings or data freshness - company appears non-reporting or dormant.

What is CSCIF's revenue and growth?

COSCIENS Biopharma Inc. reported revenue of N/A.

Does CSCIF pay dividends?

COSCIENS Biopharma Inc. does not currently pay dividends.

Where can I find CSCIF SEC filings?

Official SEC filings for COSCIENS Biopharma Inc. (CIK: 0001113423) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CSCIF's EPS?

COSCIENS Biopharma Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2026-03-23 | Powered by Claude AI